Skip to main content

Articles

Page 4 of 79

  1. The efficacy of anti-PD-1 therapy is primarily hindered by the limited T-cell immune response rate and immune evasion capacity of tumor cells. Autophagy-related protein 7 (ATG7) plays an important role in auto...

    Authors: Wenxin Zhang, Lu Chen, Jiafeng Liu, Bicui Chen, Huanying Shi, Haifei Chen, Huijie Qi, Zimei Wu, Xiang Mao, Xinhai Wang, Yuxin Huang, Jiyifan Li, Zheng Yu, Mingkang Zhong, Tianxiao Wang and Qunyi Li
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:114
    Content type: Research Published on:

  2. The dysregulated mechanistic target of rapamycin complex 1 (mTORC1) signaling plays a critical role in ferroptosis resistance and tumorigenesis. However, the precise underlying mechanisms still need to be full...

    Authors: Zixi Wang, Huaiyuan Zong, Weiwei Liu, Wei Lin, Anjiang Sun, Zhao Ding, Xu Chen, Xiaofeng Wan, Yanyan Liu, Zhongdong Hu, Hongbing Zhang, Hongwu Li, Yehai Liu, Dapeng Li, Sumei Zhang and Xiaojun Zha
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:112
    Content type: Research Published on:

  3. The regulatory role of N6-methyladenosine (m6A) modification in the onset and progression of cancer has garnered increasing attention in recent years. However, the specific role of m6A modification in pulmonar...

    Authors: Peng Ouyang, Kang Li, Wei Xu, Caiyun Chen, Yangdong Shi, Yao Tian, Jin Gong and Zhen Bao
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:111
    Content type: Research Published on:

  4. Metastasis is the leading cause of cancer-related death in non-small cell lung cancer (NSCLC) patients. We previously showed that low HERC5 expression predicts early tumor dissemination and a dismal prognosis ...

    Authors: Svenja Schneegans, Jana Löptien, Angelika Mojzisch, Desirée Loreth, Oliver Kretz, Christoph Raschdorf, Annkathrin Hanssen, Antonia Gocke, Bente Siebels, Karthikeyan Gunasekaran, Yi Ding, Leticia Oliveira-Ferrer, Laura Brylka, Thorsten Schinke, Hartmut Schlüter, Ilkka Paatero…
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:110
    Content type: Research Published on:

  5. The intravesical instillation of the paclitaxel-hyaluronan conjugate ONCOFID-P-B™ in patients with bacillus Calmette-Guérin (BCG)-unresponsive bladder carcinoma in situ (CIS; NCT04798703 phase I study), induce...

    Authors: Anna Tosi, Beatrice Parisatto, Enrico Gaffo, Stefania Bortoluzzi and Antonio Rosato
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:109
    Content type: Research Published on:

  6. Ferroptosis is a newly identified iron-dependent form of death that is becoming increasingly recognized as a promising avenue for cancer therapy. N6-methyladenosine (m6A) is the most abundant reversible methylati...

    Authors: Yaya Qiao, Meng Su, Huifang Zhao, Huanle Liu, Chenxi Wang, Xintong Dai, Lingling Liu, Guangju Liu, Huanran Sun, Mingming Sun, Jiyan Wang, Zhen Li, Jun Fan, Quan Zhang, Chunshen Li, Fangmin Situ…
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:108
    Content type: Research Published on:

    The Correction to this article has been published in Journal of Experimental & Clinical Cancer Research 2024 43:131

  7. Tumor cells have the ability to invade and form small clusters that protrude into adjacent tissues, a phenomenon that is frequently observed at the periphery of a tumor as it expands into healthy tissues. The ...

    Authors: Pedro Fonseca, Weiyingqi Cui, Nona Struyf, Le Tong, Ayushi Chaurasiya, Felipe Casagrande, Honglei Zhao, Dinura Fernando, Xinsong Chen, Nicholas P. Tobin, Brinton Seashore-Ludlow, Andreas Lundqvist, Johan Hartman, Anita Göndör, Päivi Östling and Lars Holmgren
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:107
    Content type: Research Published on:

  8. Gastric cancer (GC) is one of the leading causes of cancer-related death worldwide. Recently, targeted therapies including PD1 (programmed cell death 1) antibodies have been used in advanced GC patients. Howev...

    Authors: Daqin Suo, Xiaoling Gao, Qingyun Chen, Tingting Zeng, Jiarong Zhan, Guanghui Li, Yinli Zheng, Senlin Zhu, Jingping Yun, Xin-Yuan Guan and Yan Li
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:106
    Content type: Research Published on:

  9. Lactate has emerged as a critical regulator within the tumor microenvironment, including glioma. However, the precise mechanisms underlying how lactate influences the communication between tumor cells and tumo...

    Authors: Chaolong Yan, Zijiang Yang, Pin Chen, Yuyang Yeh, Chongjing Sun, Tao Xie, Wei Huang and Xiaobiao Zhang
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:105
    Content type: Research Published on:

  10. Cholangiocarcinoma (CCA) comprises a heterogeneous group of biliary tract cancer. Our previous CCA mutation pattern study focused on genes in the post-transcription modification process, among which the altern...

    Authors: Jiang Chang, Yaodong Zhang, Tao Zhou, Qian Qiao, Jijun Shan, Yananlan Chen, Wangjie Jiang, Yirui Wang, Shuochen Liu, Yuming Wang, Yue Yu, Changxian Li and Xiangcheng Li
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:104
    Content type: Research Published on:

  11. Brain metastasis (BM) is common among cases of advanced non-small cell lung cancer (NSCLC) and is the leading cause of death for these patients. Mesothelin (MSLN), a tumor-associated antigen expressed in many ...

    Authors: Shengkai Xia, Wenzhe Duan, Mingxin Xu, Mengqi Li, Mengyi Tang, Song Wei, Manqing Lin, Encheng Li, Wenwen Liu and Qi Wang
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:103
    Content type: Research Published on:

  12. Dysregulation of cholesterol metabolism is associated with the metastasis of triple-negative breast cancer (TNBC). Apolipoprotein A1 (ApoA1) is widely recognized for its pivotal role in regulating cholesterol ...

    Authors: Jie Dong, Lingkai Kong, Shiqun Wang, Mao Xia, Yenan Zhang, Jingyi Wu, Fuming Yang, Shuguang Zuo and Jiwu Wei
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:102
    Content type: Research Published on:

  13. Regulatory B cells (Bregs), a specialized subset of B cells that modulate immune responses and maintain immune tolerance in malignant tumors, have not been extensively investigated in the context of bladder ca...

    Authors: Jiawei Zhou, Ranran Zhou, Yuanchao Zhu, Shikai Deng, Bahaerguli Muhuitijiang, Chengyao Li, Xiaojun Shi, Ling Zhang and Wanlong Tan
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:101
    Content type: Research Published on:

  14. 5-fluorouracil (5-FU) is inefficiently converted to the active anti-cancer metabolite, fluorodeoxyuridine-monophosphate (FUDR-MP), is associated with dose-limiting toxicities and challenging administration sch...

    Authors: Pavlina Spiliopoulou, Farasat Kazmi, Francesca Aroldi, Thomas Holmes, David Thompson, Lucinda Griffiths, Cathy Qi, Matthew Parkes, Simon Lord, Gareth J. Veal, David J. Harrison, Vicky M. Coyle, Jill Graham, Thomas R. Jeffry Evans and Sarah P. Blagden
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:100
    Content type: Research Published on:

  15. Cancer stem cells (CSCs) were first discovered in the 1990s, revealing the mysteries of cancer origin, migration, recurrence and drug-resistance from a new perspective. The expression of pluripotent genes and ...

    Authors: Zhengyue Zhang and Yanjie Zhang
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:99
    Content type: Review Published on:

  16. The complement inhibitor CSMD1 acts as a tumor suppressor in various types of solid cancers. Despite its high level of expression in the brain, its function in gliomas, malignant brain tumors originating from ...

    Authors: Emre Can Tuysuz, Eleni Mourati, Rebecca Rosberg, Aleksandra Moskal, Chrysostomi Gialeli, Elinn Johansson, Valeria Governa, Mattias Belting, Alexander Pietras and Anna M. Blom
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:98
    Content type: Research Published on:

  17. CAR T cell therapy is a promising approach to improve outcomes and decrease toxicities for patients with cancer. While extraordinary success has been achieved using CAR T cells to treat patients with CD19-posi...

    Authors: Ha Won Lee, Carla O’Reilly, Alex N. Beckett, Duane G. Currier, Taosheng Chen and Christopher DeRenzo
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:97
    Content type: Research Published on:

  18. Lung cancer stands as the most prevalent form of cancer globally, posing a significant threat to human well-being. Due to the lack of effective and accurate early diagnostic methods, many patients are diagnose...

    Authors: Fei Ren, Qian Fei, Kun Qiu, Yuanjie Zhang, Heyang Zhang and Lei Sun
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:96
    Content type: Review Published on:

  19. Glioblastoma multiforme (GBM) is a highly aggressive brain tumor with a poor prognosis. Current treatment options are limited and often ineffective. CAR T cell therapy has shown success in treating hematologic...

    Authors: Xing Li, Shiyu Sun, Wansong Zhang, Ziwei Liang, Yitong Fang, Tianhu Sun, Yong Wan, Xingcong Ma, Shuqun Zhang, Yang Xu and Ruilin Tian
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:95
    Content type: Research Published on:

  20. Studies have shown that CCR7, an important inflammatory factor, can promote the proliferation and metastasis of oral squamous cell carcinoma (OSCC), but its role in the tumor microenvironment (TME) remains unc...

    Authors: Zengxu Wang, Keith L. Kirkwood, Yao Wang, Weidong Du, Shanfeng Lin, Wanhang Zhou, Cong Yan, Jiaxing Gao, Zhenning Li, Changfu Sun and Fayu Liu
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:94
    Content type: Research Published on:

  22. Based on the established role of cancer-stroma cross-talk in tumor growth, progression and chemoresistance, targeting interactions between tumor cells and their stroma provides new therapeutic approaches. Dual...

    Authors: Simona Camorani, Alessandra Caliendo, Elena Morrone, Lisa Agnello, Matteo Martini, Monica Cantile, Margherita Cerrone, Antonella Zannetti, Massimo La Deda, Monica Fedele, Loredana Ricciardi and Laura Cerchia
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:92
    Content type: Research Published on:

    The Correction to this article has been published in Journal of Experimental & Clinical Cancer Research 2024 43:243

  23. Pancreatic cancer (PC) is a highly malignant gastrointestinal tumor, which is characterized by difficulties in early diagnosis, early metastasis, limited therapeutic response and a grim prognosis. Therefore, i...

    Authors: Xiaobin Fei, Changhao Zhu, Peng Liu, Songbai Liu, Likun Ren, Rishang Lu, Junyi Hou, Yongjia Gao, Xing Wang and Yaozhen Pan
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:91
    Content type: Research Published on:

  24. Ropivacaine, a local anesthetic, exhibits anti-tumor effects in various cancer types. However, its specific functions and the molecular mechanisms involved in breast cancer cell stemness remain elusive.

    Authors: Lin Ding, Hui Jiang, Qiangwei Li, Qiushuang Li, Tian-Tian Zhang, Limeng Shang, Bin Xie, Yaling Zhu, Keshuo Ding, Xuanming Shi, Tao Zhu and Yong Zhu
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:90
    Content type: Research Published on:

  25. The evasion of the immune response by tumor cells through programmed death-ligand 1 (PD-L1) has been identified as a factor contributing to resistance to radioimmunotherapy in lung cancer patients. However, th...

    Authors: Zixuan Li, Huichan Xue, Jinsong Li, Zhikun Zheng, Zhiwei Liu, Xiaorong Dong, Hongbo Wang, Jing Chen and Shuangbing Xu
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:89
    Content type: Research Published on:

  26. This study explores the repurposing of Auranofin (AF), an anti-rheumatic drug, for treating non-small cell lung cancer (NSCLC) adenocarcinoma and pancreatic ductal adenocarcinoma (PDAC). Drug repurposing in on...

    Authors: Christophe Deben, Laurie Freire Boullosa, Felicia Rodrigues Fortes, Edgar Cardenas De La Hoz, Maxim Le Compte, Sofie Seghers, Marc Peeters, Steve Vanlanduit, Abraham Lin, Krijn K. Dijkstra, Paul Van Schil, Jeroen M. H. Hendriks, Hans Prenen, Geert Roeyen, Filip Lardon and Evelien Smits
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:88
    Content type: Research Published on:

  27. We have recently shown extensive sequence and conformational homology between tumor-associated antigens (TAAs) and antigens derived from microorganisms (MoAs). The present study aimed to assess the breadth of ...

    Authors: Beatrice Cavalluzzo, Marie Christine Viuff, Siri Amanda Tvingsholm, Concetta Ragone, Carmen Manolio, Angela Mauriello, Franco M. Buonaguro, Maria Lina Tornesello, Francesco Izzo, Alessandro Morabito, Sine Reker Hadrup, Maria Tagliamonte and Luigi Buonaguro
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:87
    Content type: Research Published on:

  28. In clear cell renal cell carcinoma (ccRCC), first-line treatment combines nivolumab (anti-PD-1) and ipilimumab (anti-CTLA4), yielding long-term remissions but with only a 40% success rate. Our study explored t...

    Authors: Christopher Montemagno, Arnaud Jacquel, Charlotte Pandiani, Olivia Rastoin, Rosie Dawaliby, Thomas Schmitt, Maxence Bourgoin, Héliciane Palenzuela, Anne-Laure Rossi, Damien Ambrosetti, Jerome Durivault, Frederic Luciano, Delphine Borchiellini, Julie Le Du, Leticia Christina Pires Gonçalves, Patrick Auberger…
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:86
    Content type: Research Published on:

  29. Anaplastic thyroid cancer (ATC) is the most aggressive thyroid cancer. Despite advances in tissue culture techniques, a robust model for ATC spheroid culture is yet to be developed. In this study, we created a...

    Authors: Jiangnan Hu, Kaili Liu, Chandrayee Ghosh, Tejinder Pal Khaket, Helen Shih and Electron Kebebew
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:85
    Content type: Research Published on:

  30. How platelets interact with and influence the tumor microenvironment (TME) remains poorly characterized.

    Authors: Ophélie Le Chapelain, Soumaya Jadoui, Angèle Gros, Samir Barbaria, Keltouma Benmeziane, Véronique Ollivier, Sébastien Dupont, Mialitiana Solo Nomenjanahary, Sabrina Mavouna, Jasmina Rogozarski, Marie-Anne Mawhin, Giuseppina Caligiuri, Sandrine Delbosc, Françoise Porteu, Bernhard Nieswandt, Pierre H Mangin…
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:84
    Content type: Research Published on:

  31. Tumor angiogenesis inhibitors have been applied for non-small cell lung cancer (NSCLC) therapy. However, the drug resistance hinders their further development. Intercellular crosstalk between lung cancer cells...

    Authors: Xueping Lei, Zhan Li, Manting Huang, Lijuan Huang, Yong Huang, Sha Lv, Weisong Zhang, Zhuowen Chen, Yuanyu Ke, Songpei Li, Jingfei Chen, Xiangyu Yang, Qiudi Deng, Junshan Liu and Xiyong Yu
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:83
    Content type: Research Published on:

  32. The paradigm of non-small cell lung cancer (NSCLC) treatment has been profoundly influenced by the development of immune checkpoint inhibitors (ICI), but the range of clinical responses observed among patients...

    Authors: Yo-Ting Tsai, Jeffrey Schlom and Renee N. Donahue
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:82
    Content type: Review Published on:

  33. Immune-checkpoint inhibitors (ICIs) have showed unprecedent efficacy in the treatment of patients with advanced non-small cell lung cancer (NSCLC). However, not all patients manifest clinical benefit due to th...

    Authors: Diego de Miguel‑Perez, Murat Ak, Priyadarshini Mamindla, Alessandro Russo, Serafettin Zenkin, Nursima Ak, Vishal Peddagangireddy, Luis Lara‑Mejia, Muthukumar Gunasekaran, Andres F. Cardona, Aung Naing, Fred R. Hirsch, Oscar Arrieta, Rivka R. Colen and Christian Rolfo
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:81
    Content type: Commentary Published on:

  34. Authors: Yu-Jiao Zhou, Min-Li Yang, Xin He, Hui-Ying Gu, Ji-Hua Ren, Sheng-Tao Cheng, Zhou Fu, Zhen-Zhen Zhang and Juan Chen
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:80
    Content type: Correction Published on:

    The original article was published in Journal of Experimental & Clinical Cancer Research 2024 43:45

  35. Acute myeloid leukemia (AML) with biallelic (CEBPAbi) as well as single mutations located in the bZIP region is associated with a favorable prognosis, but the underlying mechanisms are still unclear. Here, we pro...

    Authors: Mengbao Du, Mowang Wang, Meng Liu, Shan Fu, Yu Lin, Yankun Huo, Jian Yu, Xiaohong Yu, Chong Wang, Haowen Xiao and Limengmeng Wang
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:79
    Content type: Research Published on:

  37. The DNA damage response (DDR) is a physiological network preventing malignant transformation, e.g. by halting cell cycle progression upon DNA damage detection and promoting DNA repair. Glioblastoma are incurab...

    Authors: Bianca Walter, Sophie Hirsch, Laurence Kuhlburger, Aaron Stahl, Leonard Schnabel, Silas Wisser, Lara A. Haeusser, Foteini Tsiami, Sarah Plöger, Narges Aghaallaei, Advaita M Dick, Julia Skokowa, Christian Schmees, Markus Templin, Katja Schenke-Layland, Marcos Tatagiba…
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:77
    Content type: Research Published on:

  38. While T cell-activating immunotherapies against recurrent head and neck squamous cell carcinoma (HNSCC) have shown impressive results in clinical trials, they are often ineffective in the majority of patients....

    Authors: Fan Yang, Chenyang Yuan, Fanghui Chen, Zhaohui S. Qin, Nicole C. Schmitt, Gregory B. Lesinski, Nabil F. Saba and Yong Teng
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:76
    Content type: Research Published on:

  39. Breast Cancer (BC) can be classified, due to its heterogeneity, into multiple subtypes that differ for prognosis and clinical management. Notably, triple negative breast cancer (TNBC) – the most aggressive BC ...

    Authors: Sara Iachettini, Irene Terrenato, Manuela Porru, Serena Di Vito, Angela Rizzo, Carmen D’Angelo, Eleonora Petti, Roberto Dinami, Carmen Maresca, Anna Di Benedetto, Aldo Palange, Antonino Mulè, Angela Santoro, Antonella Palazzo, Paola Fuso, Antonella Stoppacciaro…
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:75
    Content type: Research Published on:

  40. Glutamine metabolism plays a pivotal role in cancer progression, immune cell function, and the modulation of the tumor microenvironment. Dysregulated glutamine metabolism has been implicated in cancer developm...

    Authors: Bolin Wang, Jinli Pei, Shengnan Xu, Jie Liu and Jinming Yu
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:74
    Content type: Review Published on:

    The Correction to this article has been published in Journal of Experimental & Clinical Cancer Research 2024 43:93

  41. The TGF-β signalling pathway is intricately associated with the progression of glioblastoma (GBM). The objective of this study was to examine the role of circRNAs in the TGF-β signalling pathway.

    Authors: Yuhang Wang, Binbin Wang, Wenping Cao and Xiupeng Xu
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:73
    Content type: Research Published on:

  42. The paucity of reliable biomarkers for predicting immunotherapy efficacy in patients with advanced hepatocellular carcinoma (HCC) has emerged as a burgeoning concern with the expanding use of immunotherapy. Th...

    Authors: Xiaoxuan Tu, Longxian Chen, Yi Zheng, Chenglin Mu, Zhiwei Zhang, Feiyu Wang, Yiqing Ren, Yingxin Duan, Hangyu Zhang, Zhou Tong, Lulu Liu, Xunqi Sun, Peng Zhao, Lie Wang, Xinhua Feng, Weijia Fang…
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:72
    Content type: Research Published on:

  43. A firm link between endoplasmic reticulum (ER) stress and tumors has been wildly reported. Endoplasmic reticulum oxidoreductase 1 alpha (ERO1α), an ER-resident thiol oxidoreductase, is confirmed to be highly u...

    Authors: Peng Chen, Amit Sharma, Hans Weiher and Ingo G.H. Schmidt-Wolf
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:71
    Content type: Review Published on:

  44. The combination of radiotherapy and immunotherapy (immunoradiotherapy) has been increasingly used for treating a wide range of cancers. However, some tumors are resistant to immunoradiotherapy. We have previou...

    Authors: Yun Hu, Alexey Revenko, Hampartsoum Barsoumian, Genevieve Bertolet, Natalie Wall Fowlkes, Hadi Maazi, Morgan Maureen Green, Kewen He, Duygu Sezen, Tiffany A. Voss, Claudia S Kettlun Leyton, Fatemeh Masrorpour, Zahid Rafiq, Nahum Puebla-Osorio, Carola Leuschner, Robert MacLeod…
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:70
    Content type: Research Published on:

  45. Head and neck squamous carcinoma (HNSCC) is known for its high aggressiveness and susceptibility to cervical lymph node metastasis, which greatly contributes to its poor prognosis. During tumorigenesis, many t...

    Authors: Hongshi Cai, Jianfeng Liang, Yaoqi Jiang, Ziyi Wang, Hongyu Li, Wenjin Wang, Cheng Wang and Jinsong Hou
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:69
    Content type: Research Published on:

  46. Proteasome inhibitors (PIs) are one of the most important classes of drugs for the treatment of multiple myeloma (MM). However, almost all patients with MM develop PI resistance, resulting in therapeutic failu...

    Authors: Xiaobin Wang, Yingqing Shi, Hua Shi, Xiaoyu Liu, Aijun Liao, Zhuogang Liu, Robert Z. Orlowski, Rui Zhang and Huihan Wang
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:68
    Content type: Research Published on:

  47. Docetaxel resistance represents a significant obstacle in the treatment of prostate cancer. The intricate interplay between cytokine signalling pathways and transcriptional control mechanisms in cancer cells c...

    Authors: Bisheng Cheng, Lingfeng Li, Tianlong Luo, Qiong Wang, Yong Luo, Shoumin Bai, Kaiwen Li, Yiming Lai and Hai Huang
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:67
    Content type: Research Published on:

  48. CRISPR/Cas9 system to treat human-related diseases has achieved significant results and, even if its potential application in cancer research is improving, the application of this approach in clinical practice...

    Authors: M Caforio, S Iacovelli, C Quintarelli, F Locatelli and Valentina Folgiero
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:66
    Content type: Review Published on:

  49. Cingulin (CGN) is a pivotal cytoskeletal adaptor protein located at tight junctions. This study investigates the link between CGN mutation and increased cancer susceptibility through genetic and mechanistic analy...

    Authors: Yi-Ting Huang, Ya-Ting Hsu, Pei-Ying Wu, Yu-Min Yeh, Peng-Chan Lin, Keng-Fu Hsu and Meng-Ru Shen
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:65
    Content type: Research Published on:

  50. Colorectal cancer (CRC) is a heterogenous malignancy underpinned by dysregulation of cellular signaling pathways. Previous literature has implicated aberrant JAK/STAT3 signal transduction in the development an...

    Authors: Kathryn A. F. Pennel, Phimmada Hatthakarnkul, Colin S. Wood, Guang-Yu Lian, Sara S. F. Al-Badran, Jean A. Quinn, Assya Legrini, Jitwadee Inthagard, Peter G. Alexander, Hester van Wyk, Ahmad Kurniawan, Umar Hashmi, Michael A. Gillespie, Megan Mills, Aula Ammar, Jennifer Hay…
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:64
    Content type: Research Published on:

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 11.4
    5-year Journal Impact Factor: 11.4
    Source Normalized Impact per Paper (SNIP): 1.770
    SCImago Journal Rank (SJR): 2.806

    Speed 2023
    Submission to first editorial decision (median days): 5
    Submission to acceptance (median days): 100

    Usage 2023
    Downloads: 3,003,080
    Altmetric mentions: 3,022

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us